We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

41 hedge funds and large institutions have $7.97M invested in Tempest Therapeutics in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 50 → 41 (-9)

46% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 13

60% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 15

64% less capital invested

Capital invested by funds: $21.9M → $7.97M (-$14M)

Holders
41
Holders Change
-9
Holders Change %
-18%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
13
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$884K
2
GC
GMT Capital
Georgia
+$821K
3
Wells Fargo
Wells Fargo
California
+$333K
4
VF
Virtu Financial
New York
+$129K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$114K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5M
2
Jennison Associates
Jennison Associates
New York
-$3.06M
3
Deutsche Bank
Deutsche Bank
Germany
-$522K
4
LCM
Laurion Capital Management
New York
-$461K
5
BCM
BBT Capital Management
Texas
-$355K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$30K +$3K +1 +8%
Two Sigma Investments
27
Two Sigma Investments
New York
$28K -$213K -71 -86%
Russell Investments Group
28
Russell Investments Group
United Kingdom
$22K – – –
Two Sigma Advisers
29
Two Sigma Advisers
New York
$21K -$18K -6 -40%
State Street
30
State Street
Massachusetts
$16K – – –
GC
31
Guggenheim Capital
Illinois
$9K – – –
EAM
32
Eagle Asset Management
Florida
$8K +$12K +4 New
Deutsche Bank
33
Deutsche Bank
Germany
$7K -$522K -174 -98%
Morgan Stanley
34
Morgan Stanley
New York
$5K +$3K +1 +100%
MAM
35
Meeder Asset Management
Ohio
$4K – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$3K -$89.9K -30 -97%
TIM
37
Tortoise Investment Management
New York
$3K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$3K +$3K +1 New
Federated Hermes
39
Federated Hermes
Pennsylvania
$2K – – –
UBS Group
40
UBS Group
Switzerland
$1K -$8.99K -3 Closed
Citigroup
41
Citigroup
New York
$1K -$3K -1 -50%
Bank of America
42
Bank of America
North Carolina
$1K – – –
Bank of Montreal
43
Bank of Montreal
Ontario, Canada
$1K – – –
BWM
44
Baystate Wealth Management
Massachusetts
$1K – – –
PAM
45
Panagora Asset Management
Massachusetts
$1K – – –
TCOV
46
Trust Company of Vermont
Vermont
$1K – – –
RE
47
RBC Europe
United Kingdom
$81 – – –
Fidelity Investments
48
Fidelity Investments
Massachusetts
– -$5M -1,222 Closed
Jennison Associates
49
Jennison Associates
New York
– -$3.06M -748 Closed
LCM
50
Laurion Capital Management
New York
– -$461K -113 Closed
1
2
3

TPST Hedge Fund Activity: Q1 2018 in Review

41 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2018, worth a combined $7.97M — down 64% from $21.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TPST and 6 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 7 added.

The largest buyer was Sabby Management, adding an estimated $884K. The largest seller was Fidelity Investments, exiting entirely with an estimated $5M sold.

  • 41 institutional investors held Tempest Therapeutics (TPST) as of Q1 2018, down from 50 in Q4 2017.
  • Funds reported $7.97M of Tempest Therapeutics stock for Q1 2018, down 64% quarter-over-quarter.
  • 6 funds opened new Tempest Therapeutics positions in Q1 2018 and 15 closed out, a net change of -9 holders.
  • The largest Tempest Therapeutics buyer in Q1 2018 was Sabby Management, an estimated $884K added.
  • The largest Tempest Therapeutics seller in Q1 2018 was Fidelity Investments, an estimated $5M sold.

Based on aggregated 13F filings for Q1 2018.